Hung-Yi Chen1,2, Jiun-Jie Lin3,4, Bo Yang5, Mei-Chen Lin6,7. 1. Institute of Pharmacy, China Medical University, Taichung, Taiwan. 2. Department of Pharmacy, China Medical University Hospital, Beikang Campus, Yunlin, Taiwan. 3. Department of Pharmacy, Feng-Yuan Hospital, Ministry of Health Welfare, No. 100 An-Kan Rd., Fengyuan Dist., Taichung City, 42055, Taiwan, Republic of China. baicalin1@gmail.com. 4. Taichung City New Pharmacist Association, Taichung, Taiwan. baicalin1@gmail.com. 5. Institute of Lipids Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou, China. 6. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan. 7. College of Medicine, China Medical University, Taichung, Taiwan.
Abstract
INTRODUCTION: The risk factors for systemic autoimmune diseases (SAD) in gastric disease patients with proton pump inhibitor (PPI) use are still unclear. This study discussed this relationship in an Asian population. METHODS: Patients without a prior history of SAD were identified from Taiwan's National Health Insurance Research Database between January 1, 2000, and December 31, 2010. Cox regression models were applied to estimate the hazard ratio (HR) with 95% confidence interval [CI] of SAD. The cumulative PPI dosage was stratified by quartiles of defined daily doses and adjusted for baseline disease risk score which served as the primary variables compared against no PPI use. RESULTS: We analyzed the data of 51,291 participants aged 18 years or older and free of SAD at baseline. PPI users (n = 17,938) had a significantly increased risk of SAD over non-PPI users. There was a significantly higher risk of developing SAD in older age groups. A significant dose-dependent association was observed between cumulative PPI use and the risk of SAD. Female PPI users had significantly higher risk of developing SAD. In patients who received PPI, the autoimmune disease with significantly higher incidence was Sjögren syndrome (SjS) (adjusted HR [aHR] 1.82, 95% CI, 1.02-3.27) and rheumatoid arthritis (RA) (aHR, 2.19, 95% CI, 1.19-4.01). CONCLUSION: This study found PPI users to be associated with an increased risk of SAD. Older age or cumulative PPI use was significantly associated with SAD, and the highest incidence was SjS and RA among gastric disease patients who received PPI. Key Points • This nationwide long-term cohort study found PPI users to be associated with an increased risk of rheumatoid arthritis and Sjögren syndrome in Taiwan. • This finding may help with clinical risk evaluation and will inform further investigation of the pathogenesis between autoimmune diseases and PPI use.
INTRODUCTION: The risk factors for systemic autoimmune diseases (SAD) in gastric diseasepatients with proton pump inhibitor (PPI) use are still unclear. This study discussed this relationship in an Asian population. METHODS:Patients without a prior history of SAD were identified from Taiwan's National Health Insurance Research Database between January 1, 2000, and December 31, 2010. Cox regression models were applied to estimate the hazard ratio (HR) with 95% confidence interval [CI] of SAD. The cumulative PPI dosage was stratified by quartiles of defined daily doses and adjusted for baseline disease risk score which served as the primary variables compared against no PPI use. RESULTS: We analyzed the data of 51,291 participants aged 18 years or older and free of SAD at baseline. PPI users (n = 17,938) had a significantly increased risk of SAD over non-PPI users. There was a significantly higher risk of developing SAD in older age groups. A significant dose-dependent association was observed between cumulative PPI use and the risk of SAD. Female PPI users had significantly higher risk of developing SAD. In patients who received PPI, the autoimmune disease with significantly higher incidence was Sjögren syndrome (SjS) (adjusted HR [aHR] 1.82, 95% CI, 1.02-3.27) and rheumatoid arthritis (RA) (aHR, 2.19, 95% CI, 1.19-4.01). CONCLUSION: This study found PPI users to be associated with an increased risk of SAD. Older age or cumulative PPI use was significantly associated with SAD, and the highest incidence was SjS and RA among gastric diseasepatients who received PPI. Key Points • This nationwide long-term cohort study found PPI users to be associated with an increased risk of rheumatoid arthritis and Sjögren syndrome in Taiwan. • This finding may help with clinical risk evaluation and will inform further investigation of the pathogenesis between autoimmune diseases and PPI use.
Entities:
Keywords:
Asian population; Proton pump inhibitor; Rheumatoid arthritis; Sjögren syndrome
Authors: S Manfredo Vieira; M Hiltensperger; V Kumar; D Zegarra-Ruiz; C Dehner; N Khan; F R C Costa; E Tiniakou; T Greiling; W Ruff; A Barbieri; C Kriegel; S S Mehta; J R Knight; D Jain; A L Goodman; M A Kriegel Journal: Science Date: 2018-03-09 Impact factor: 47.728
Authors: Taco A van der Meulen; Hermie J M Harmsen; Arnau Vich Vila; Alexander Kurilshikov; Silvia C Liefers; Alexandra Zhernakova; Jingyuan Fu; Cisca Wijmenga; Rinse K Weersma; Karina de Leeuw; Hendrika Bootsma; Fred K L Spijkervet; Arjan Vissink; Frans G M Kroese Journal: J Autoimmun Date: 2018-11-09 Impact factor: 7.094
Authors: Floris Imhann; Marc Jan Bonder; Arnau Vich Vila; Jingyuan Fu; Zlatan Mujagic; Lisa Vork; Ettje F Tigchelaar; Soesma A Jankipersadsing; Maria Carmen Cenit; Hermie J M Harmsen; Gerard Dijkstra; Lude Franke; Ramnik J Xavier; Daisy Jonkers; Cisca Wijmenga; Rinse K Weersma; Alexandra Zhernakova Journal: Gut Date: 2015-12-09 Impact factor: 23.059